The AGGF1 Knockout KYSE-30 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human esophageal squamous cell carcinoma cell line KYSE-30 by targeted disruption of the AGGF1 gene. This polyclonal knockout model provides a heterogeneous loss-of-function system to investigate AGGF1-dependent processes. It is intended for advanced research in cancer biology, angiogenesis, and DNA repair.
KYSE-30 is a well-differentiated esophageal squamous cell carcinoma line established from a Japanese patient. This adherent cell line serves as a physiologically relevant model for studying esophageal cancer pathogenesis, including tumor cell proliferation, migration, and invasion. Its use as the host background for AGGF1 knockout enables the dissection of gene function within an oncogenic epithelial context, directly applicable to esophageal squamous cell carcinoma biology.
AGGF1 functions as an angiogenic factor and DNA repair mediator. It is transcriptionally regulated by HIF1A and NF-??B under hypoxia and genotoxic stress. AGGF1 promotes angiogenesis by inducing VEGFA expression and activates downstream AKT and ERK1/2 signaling, while also upregulating MMP9. In DNA repair, AGGF1 interacts with Fanconi anemia pathway components FANCD2 and BRCA2, and with non-homologous end joining factors Ku70 (XRCC6), Ku80 (XRCC5), and XRCC4, contributing to genomic stability. Knockout of AGGF1 therefore disrupts both angiogenic signaling and DNA damage response networks.
Within the KYSE-30 esophageal cancer model, AGGF1 knockout is particularly relevant for examining how loss of angiogenic support and impaired DNA repair influence tumor biology. Esophageal squamous cell carcinomas rely on robust angiogenesis and DNA damage tolerance for progression. Disruption of AGGF1 is expected to attenuate VEGFA-driven angiogenesis, reduce pro-survival AKT and ERK1/2 phosphorylation, and compromise DNA repair, potentially enhancing sensitivity to DNA-damaging therapeutics. This polyclonal population enables the study of heterogeneous knockout effects on these processes.
Typical research applications include investigating AGGF1??s role in tumor angiogenesis, DNA repair pathways, NF-??B signaling, and drug response in esophageal cancer. Validated assays for this model include MTT proliferation assays, wound healing and Transwell invasion assays, Annexin V apoptosis assays, VEGF ELISA, western blotting for phospho-AKT and phospho-ERK1/2, NF-??B luciferase reporter assays, and immunofluorescence for gamma-H2AX foci. These applications facilitate drug screening and mechanistic studies. For further information, please contact Ascent Research.
